Summary
Ftorafur (FT), a 2-tetrahydrofuryl derivative of 5-fluorouracil (5-FU) was introduced into cancer chemotherapy with the hope to obtain a therapeutic effect comparable to 5-FU with a smaller dose and less side effects. A comparison of the effect of FT and 5-FU on the proliferation of L 1210 ascites tumor cells in the present work has shown that both drugs result in an inhibition of DNA synthesis due to an inhibition of thymidylate synthetase. However, the extent of the effect of FT is reduced, i.e., to achieve a cell kinetic effect comparable to that of 5-FU, 60 times the equimolecular FT dose has to be applied. Thus, there is no dose-saving effect of FT compared to 5-FU. A depotlike 5-FU effect of FT due to a slow release of 5-FU from FT as described in the literature could not be confirmed in the present study either. The effect of FT on the proliferation of L 1210 ascites tumor cells did not last longer than that of 5-FU. In contrast to 5-FU a severe side effect, viz., a drastic decrease of the body temperature from 39.1 °C to 31.6°C, was observed. That means that FT cannotonly be effective by a release of 5-FU. This toxic side effect must be due to a different mechanism of action of FT. A significant increase in the median life span could only be achieved by the application of 5-FU (180 μg/g). An equimolecular FT-dose did not result in an increase of the median life span. Based on the present study, the advantages of FT compared to 5-FU described in the literature cannot be confirmed. The present work shows that cell kinetic studies in animals are a useful tool to test the effect of new drugs in chemotherapy.
Similar content being viewed by others
References
Belt RJ, Stephens R (1979) Phase I–II study of ftorafur and methyl-CCNU in advanced colorectal cancer. Cancer 44:869–872
Benvenuto JA, Lu K, Hall SW, Benjamin RS, Loo TL (1978) Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans. Cancer Res 38:3867–3870
Buroker T, Baker L, Correa J, Schwartz LA, Vaitkevicius VK (1977a) Phase I trial of ftorafur combined with mitomycin C or methyl-CCNU in gastrointestinal cancers. Cancer Treat Rep 61:463–467
Buroker T, Miller A, Baker L, McKenzie M, Samson M, Vaitkevicius VK (1977b) Phase II clinical trial of ftorafur in 5-fluorouracil-refractory colorectal cancer. Cancer Treat Rep 61:1579–1580
Buroker T, Padilla F, Groppe C, Guy G, Quagliana J, McCracken J, Vaitkevicius VK, Hoogstraten B, Heilbrun L (1979) Phase II evaluation of ftorafur in previously untreated colorectal cancer. Cancer 44:48–51
Camplejohn RS, Schulze B, Maurer W (1977) In vivo cell synchrony in the L 1210 mouse leukaemia studied with 5-fluorouracil or 5-flourouracil followed by cold thymidine infusion. Br J Cancer 35:546–556
Camplejohn RS, Jellinghaus W, Parussel W, Schultze B, Maurer W (1978) Attempt to achieve in vivo synchrony in mouse L 1210 leukemia with fluorouracil. In: Siegenthaler W, Lüthy R (eds) Current chemotherapy: Proc 10th Int Congr Chemotherapy, American Society for Microbiology. Washington, pp 1171–1173
Cohen AM (1975) The disposition of ftorafur in rats after intravenous administration. Drug Metab Dispos 3:303–308
Diggs CH, Wiernik PH, Smyth AC (1977) Iv methyl-CCNU and ftorafur with or without methanol-extracted residue of BCG for metastatic adenocarcinoma of the colon. Cancer Treat Rep 61:1581–1583
Freudenthal R, Emmerling DC (1977) The metabolism of ftorafur in the beagle dog and rhesus monkey. Xenobiotika 7:757–764
Fuji S, Okuda H (1974) Studies on antitumor activity of N1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207). In: Daikos GK (ed) Progress in chemotherapy, Vol III: Antineoplastic chemotherapy (proc 8. Int Congr Chemotherapy, Athens, 1973) pp 669–679
Fujimoto S, Akao T, Itoh B, Koshizuka I, Koyano K, Kitsukawa Y, Takahashi M, Minami T, Ishigami H, Nomura Y, Itoh K (1976) Effect of N1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil on nucleic acid and protein biosyntheses in Ehrlich ascites cells. Cancer Res 36:33–33
Fujita H, Kimura K (1974) In vivo distribution and metabolism of N1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207). In: Daikos GK (ed) Progress in chemotherapy, Vol III: Antineoplastic chemotherapy (Proc 8. Int Congr Chemotherapy, Athens, 1973) pp 159–165
Fujita H, Sugiyama M, Kimura K (1976) Pharmacokinetics of futraful (FT-207) for clinical application. Chemotherapy 8:51–57
Garibjanian BT, Johnson RK, Kline I, Vadlamudi S, Gang M, Venditti JM, Goldin A (1976) Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors. Cancer Treat Rep 60:1347–1361
Hall SW, Valdivieso M, Benjamin RS (1977) Intermittent high single-dose ftorafur: Phase I clinical trial with a pharmacologic toxicity correlation. Cancer Treat Rep 61:1495–1498
Hartmann KU, Heidelberger C (1961) Studies on fluorinated pyrimidines. XIII. Inhition of thymidine synthesis. J Biol Chem 236:3006–3013
Hiller SA, Zhuk RA, Lidak MY (1967) Analogs of pyrimidine nucleosides. I. N1-(2-tetrahydrofuryl) derivates of natural pyrimidine bases and their antimetabolites. Dokl Acad Nauk SSSR 176:332–335
Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Burgess MA, Livingston RB Valdivieso M, Gutterman JU, Hersh EM, Bodey GP (1979) Ftorafur, adriamycin, cyclophosphamide, and BCG in the treatment of metastatic breast cancer. Cancer 44:398–405
Johnson RK, Garibjanian BT, Houchens DP, Kline I, Gaston MR, Syrkin AB, Goldin A (1976) Comparison of 5-fluorouracil and ftorafur. I. Quantitative and qualitative differences in toxicity to mice. Cancer Treat Rep 60:1335–1345
Karev N, Blokhina N, Voznyi E, Pershin M (1974) Valutazione comparativa della efficacie del fluorofure (Ftorafur) e del 5-fluorouracile (5-ftouracil) per la cura del cancro della ghiandola mammaria. Minerva Medica 65:2811–2814
Klippel KF, Sorger K, Hill J, Jacobi G (1979) Intratumorale Chemotherapie beim Harnblasen-Carcinom 1. Erfahrungsbericht. Akt Urol 10:275–280
Pallavicini MG, Cohen AM, Dethlefsen LA, Gray JW (1979) In vivo effects of 5-fluorouracil and ftorafur (1-tetrahydrofuran-2-yl-5-fluorouracil) on murine mammary tumors and small intestine. Cell Tissue Kinet 12:177–189
Sachs L (1974) Angewandte Statistik; Planung und Auswertung—Methoden und Modelle. Springer, Berlin Heidelberg New York, 4. Aufl, S 230
Sadee W, Wong CG (1977) Research review: Pharmacokinetics of 5-fluorouracil: Inter-relationship with biochemical kinetics in monitoring therapy. Clin Pharmacokinet 2:437–450
Schnitzler G, Queisser W, Arnold H, Drings P, Fritze D, Geldmacher J, Hager T, Hartwich G, Kempf P, Meiser RJ, Nedden R, Olderhausen v H-F, Pappas A, Roemeling v R, Sievers H, Wahrendorf J, Westerhausen M, Witte S (1980) Eine randomisierte Phase III-Studie bei metastasierten gastrointestinalen Carcinomen. Vergleich zwischen 5-Fluorouracil-Carmustin-Vincristin und Ftorafur-Carmustin-Vincristin. Deutscher Krebskongreß 1980 München
Schultze B, Maidhof R, Maurer W (1975) Percent labelled mitoses method modified by double labelling with 3H-and 14C-thymidine. Determination of cell kinetic parameters in L 1210 ascites tumor cells. 7th ESGCP, Amsterdam
Unemi N, Harima K, Daidai Y, Fujihara H, Fujii S (1971) Experimental studies of N1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) Jap J Cancer Clin 17:731–744
Valdivieso M, Bodey GP, Gottlieb JA, Freireich EJ (1976) Clinical evaluation of ftorafur (pyrimidine-deoxyribose N1-2′ furanidyl-5-fluorouracil). Cancer Res 36:1821–1824
Valdivieso M, Bedikian A, Burgess MA, Rodriguez V, Hersh EM, Bodey GP, Mavligit GM (1977) Chemoimmunotherapy of metastastic large bowel cancer. Cancer 40:2731–2739
van Putten LM, Lelieveld P, Pantarotto C, Salmona M, Spreafico F (1979) Ftorafur: A self-limiting source of 5-fluorouracil? Cancer Chemother Pharmacol 3:61–66
Wu AT, Au JL, Sadee W (1978) Hydroxylated metabolites of R, S-1-(Tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) in rats and rabbits. Cancer Res 38:210–214
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schultze, B., Jellinghaus, W., Weis, G. et al. Comparing cell kinetic studies of the effect of ftorafur and 5-fluorouracil on the L 1210 ascites tumor. J Cancer Res Clin Oncol 100, 25–40 (1981). https://doi.org/10.1007/BF00405899
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00405899